NHAS
BBOT

Novo Holdings A/S’s BridgeBio Oncology BBOT Stock Holding History

Novo Holdings A/S’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.1M Buy
2,250,000
+64,077
+3% +$535K 1% 22
2026
Q1 		$19.6M Buy
2,185,923
+224,606
+11% +$2.41M 1.59% 19
2025
Q4 		$24.6M Hold
1,961,317
– – 1.91% 19
2025
Q3 		$22.7M Buy
+1,961,317
New +$20.4M 1.46% 21

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Novo Holdings A/S's BBOT Position: Q2 2026 in Review

Novo Holdings A/S increased its BridgeBio Oncology (BBOT) stake by 2.9% in Q2 2026, buying an estimated $535K and bringing the position to 2,250,000 shares worth $17.1M. The position accounts for 1% of the portfolio, ranked #22.

Novo Holdings A/S first reported a position in BBOT in Q3 2025 and has held it in 4 quarters since. The position peaked at $24.6M in Q4 2025. 65 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • Novo Holdings A/S held 2,250,000 shares of BridgeBio Oncology worth $17.1M as of Q2 2026.
  • Novo Holdings A/S bought 64,077 BridgeBio Oncology shares in Q2 2026, an estimated $535K.
  • BridgeBio Oncology made up 1% of Novo Holdings A/S's portfolio in Q2 2026, its #22 holding.
  • Novo Holdings A/S first reported a position in BridgeBio Oncology in Q3 2025 and has held it in 4 quarters since.
  • Novo Holdings A/S's BridgeBio Oncology position peaked at $24.6M in Q4 2025.
  • 65 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Novo Holdings A/S's 13F filing for Q2 2026, filed 14 Aug 2026.